This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Neutropaenic sepsis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • neutropenic sepsis is a potentially fatal complication of anticancer treatment (particularly chemotherapy)
    • mortality rates ranging between 2% and 21% have been reported in adults. Aggressive use of inpatient intravenous antibiotic therapy has reduced morbidity and mortality rates and intensive care management is now needed in fewer than 5% of cases in England

When to refer patients in the community for suspected neutropenic sepsis

  • suspect neutropenic sepsis in patients having anticancer treatment who become unwell
  • refer patients with suspected neutropenic sepsis immediately for assessment in secondary or tertiary care

confirming a diagnosis of neutropenic sepsis

  • diagnose neutropenic sepsis in patients having anticancer treatment whose neutrophil count is 0.5 × 10^9 per litre or lower and who have either:
    • a temperature higher than 38 deg or other signs or
    • symptoms consistent with clinically significant sepsis.

Managing suspected neutropenic sepsis in secondary and tertiary care

Emergency treatment and assessment

  • treat suspected neutropenic sepsis as an acute medical emergency and offer empiric antibiotic therapy immediately
  • in the initial clinical assessment of patients with suspected neutropenic sepsis:
    • history and examination
    • full blood count, kidney and liver function tests (including albumin), C-reactive protein, lactate and blood culture
  • further assessment
    • try to identify the underlying cause of the sepsis by carrying out:
      • additional peripheral blood culture in patients with a central venous access device if clinically feasible
      • urinalysis in all children aged under 5 years.

antibiotic therapy

  • beta lactam monotherapy with piperacillin with tazobactam should be offered as initial empiric antibiotic therapy to patients with suspected neutropenic sepsis who need intravenous treatment unless there are patient-specific or local microbiological contraindications
  • an aminoglycoside should not be offered, either as monotherapy or in dual therapy, for the initial empiric treatment of suspected neutropenic sepsis unless there are patient-specific or local microbiological indications

Notes:

  • reducing the risk of septic complications of anticancer treatment
    • for adult patients (aged 18 years and older) with acute leukaemias, stem cell transplants or solid tumours in whom significant neutropenia (neutrophil count 0.5×10^9 per litre or lower) is an anticipated consequence of chemotherapy, offer prophylaxis with a fluoroquinolone during the expected period of neutropenia only
    • rates of antibiotic resistance and infection patterns should be monitored in treatment facilities where patients are having fluoroquinolones for the prophylaxis of neutropenic sepsis
    • do not routinely offer G-CSF for the prevention of neutropenic sepsis in adults receiving chemotherapy unless they are receiving G-CSF as an integral part of the chemotherapy regimen or in order to maintain dose intensity

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.